A number of research firms have changed their ratings and price targets for Ultragenyx Pharmaceutical (NASDAQ: RARE):

  • 10/12/2018 – Ultragenyx Pharmaceutical was downgraded by analysts at ValuEngine from a “strong-buy” rating to a “buy” rating.
  • 10/9/2018 – Ultragenyx Pharmaceutical was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 10/8/2018 – Ultragenyx Pharmaceutical was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Ultragenyx launched its second drug, Crysvita, in the United States to treat X-linked hypophosphatemia (XLH) in April. We are optimistic on the drug’s uptake. The drug was also approved in the EU in February on a conditional basis. In May, the company announced positive phase II data from the drug in pediatric setting, but according to the FDA those were not sufficient to support an NDA. Thus, the company is in discussions with FDA and EMA, which would provide further clarity regarding whether an additional study would be required for the approval. The company also remains focused on its two-gene therapy programs — DTX301 for ornithine transcarbamylase deficiency and DTX401 for glycogen storage disease type Ia. However, developmental or regulatory setbacks could result in higher operating expenses and the need for additional capital. Loss estimates have narrowed ahead of  Q3 earnings release.”
  • 10/7/2018 – Ultragenyx Pharmaceutical had its “buy” rating reaffirmed by analysts at JPMorgan Chase & Co.. They now have a $86.00 price target on the stock. They wrote, “Ahead of the pending Phase 3 results for UX007 (trihep) in Glut1 DS expected sometime this quarter, we sifted through early data and market sizing assumptions to frame expectations and potential upside/downside on the event. Bottom line, while directly comparable data are limited to say the least (most similar pilot study only had an N of 6 and Phase 2 trials evaluated different endpoints), we believe a positive read- out is the most likely outcome given proof of concept data combined with seemingly reasonable powering assumptions. Between the recent pullback in shares (15% since 9/25) and our sense that this opportunity is not well understood by the market, we see risk/reward slightly skewed to the upside. Maintain OW.””
  • 10/3/2018 – Ultragenyx Pharmaceutical was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $86.00 price target on the stock. According to Zacks, “Ultragenyx launched its second drug, Crysvita, in the United States to treat X-linked hypophosphatemia (XLH) in April. We are optimistic on the drug’s uptake. The drug was also approved in the EU in February on a conditional basis. In May, the company announced positive phase II data from the drug in pediatric setting, but according to the FDA those were not sufficient to support an NDA. Thus, the company is in discussions with FDA and EMA, which would provide further clarity regarding whether an additional study would be required for the approval. The company also remains focused on its two-gene therapy programs — DTX301 for ornithine transcarbamylase deficiency and DTX401 for glycogen storage disease type Ia. However,developmental or regulatory setbacks could result in higher operating expenses and the need for additional capital. “
  • 9/29/2018 – Ultragenyx Pharmaceutical was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 9/11/2018 – Ultragenyx Pharmaceutical had its price target raised by analysts at Bank of America Corp from $72.00 to $94.00. They now have a “buy” rating on the stock.
  • 9/10/2018 – Ultragenyx Pharmaceutical had its “equal weight” rating reaffirmed by analysts at Morgan Stanley. They now have a $92.00 price target on the stock.
  • 9/2/2018 – Ultragenyx Pharmaceutical had its “buy” rating reaffirmed by analysts at JMP Securities. They now have a $94.00 price target on the stock.
  • 9/1/2018 – Ultragenyx Pharmaceutical was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 8/30/2018 – Ultragenyx Pharmaceutical had its price target raised by analysts at Wedbush from $80.00 to $90.00. They now have an “outperform” rating on the stock.
  • 8/29/2018 – Ultragenyx Pharmaceutical was upgraded by analysts at ValuEngine from a “buy” rating to a “strong-buy” rating.
  • 8/29/2018 – Ultragenyx Pharmaceutical had its “buy” rating reaffirmed by analysts at JPMorgan Chase & Co..
  • 8/20/2018 – Ultragenyx Pharmaceutical had its price target raised by analysts at SunTrust Banks, Inc. to $83.00. They now have a “positive” rating on the stock.

Shares of NASDAQ RARE traded up $2.49 during mid-day trading on Tuesday, reaching $64.28. The company’s stock had a trading volume of 10,994 shares, compared to its average volume of 525,441. The stock has a market capitalization of $3.83 billion, a price-to-earnings ratio of -8.57 and a beta of 1.95. Ultragenyx Pharmaceutical Inc has a 1-year low of $41.67 and a 1-year high of $90.98.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($1.06) EPS for the quarter, beating the Zacks’ consensus estimate of ($2.08) by $1.02. Ultragenyx Pharmaceutical had a negative net margin of 703.27% and a negative return on equity of 44.09%. The business had revenue of $12.79 million during the quarter, compared to analysts’ expectations of $5.63 million. During the same period in the prior year, the business earned ($1.72) earnings per share. Equities research analysts expect that Ultragenyx Pharmaceutical Inc will post -4.4 earnings per share for the current fiscal year.

In other news, Director William Aliski sold 3,750 shares of the firm’s stock in a transaction dated Wednesday, August 8th. The stock was sold at an average price of $76.66, for a total transaction of $287,475.00. Following the completion of the sale, the director now directly owns 72,610 shares of the company’s stock, valued at approximately $5,566,282.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Shalini Sharp sold 6,700 shares of the firm’s stock in a transaction dated Tuesday, September 25th. The stock was sold at an average price of $90.07, for a total value of $603,469.00. Following the sale, the chief financial officer now directly owns 56,828 shares of the company’s stock, valued at $5,118,497.96. The disclosure for this sale can be found here. Insiders have sold a total of 35,000 shares of company stock valued at $2,700,774 over the last ninety days. Company insiders own 8.40% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of RARE. Advisors Asset Management Inc. acquired a new stake in Ultragenyx Pharmaceutical in the 2nd quarter valued at approximately $181,000. Hsbc Holdings PLC bought a new position in shares of Ultragenyx Pharmaceutical during the first quarter valued at about $213,000. JBF Capital Inc. bought a new position in shares of Ultragenyx Pharmaceutical during the second quarter valued at about $384,000. Strs Ohio raised its stake in shares of Ultragenyx Pharmaceutical by 358.3% during the second quarter. Strs Ohio now owns 5,500 shares of the biopharmaceutical company’s stock valued at $422,000 after acquiring an additional 4,300 shares during the last quarter. Finally, Pier 88 Investment Partners LLC bought a new position in shares of Ultragenyx Pharmaceutical during the second quarter valued at about $446,000. 96.09% of the stock is owned by institutional investors.

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.

Featured Article: Asset Allocation and Your Retirement

Receive News & Ratings for Ultragenyx Pharmaceutical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc and related companies with MarketBeat.com's FREE daily email newsletter.